$BIO Sina Finance reports that Japanese pharmaceutical company Shionogi will acquire IntraBio for $2 billion. IntraBio’s expertise will significantly strengthen Shionogi’s rare disease R&D pipeline. Through the transaction, Shionogi will obtain all global rights to Aqneursa, including its intellectual property and commercialization rights. The drug has been approved in the United States and the European Union to treat neurological symptoms caused by Niemann-Pick disease type C. Shionogi will acquire IntraBio shares from existing shareholders, including individuals, trusts, and corporations, with the deal expected to close between November and December.